Inhibitors of Protein Kinase A Localization in the Heart

Information

  • Research Project
  • 6882485
  • ApplicationId
    6882485
  • Core Project Number
    R43HL079788
  • Full Project Number
    1R43HL079788-01
  • Serial Number
    79788
  • FOA Number
  • Sub Project Id
  • Project Start Date
    3/1/2005 - 19 years ago
  • Project End Date
    8/31/2005 - 19 years ago
  • Program Officer Name
    BUXTON, DENIS B.
  • Budget Start Date
    3/1/2005 - 19 years ago
  • Budget End Date
    8/31/2005 - 19 years ago
  • Fiscal Year
    2005
  • Support Year
    1
  • Suffix
  • Award Notice Date
    2/21/2005 - 19 years ago

Inhibitors of Protein Kinase A Localization in the Heart

DESCRIPTION (provided by applicant): Cell permeable peptide inhibitors of protein kinase (PKA) sub-cellular localization will be designed to identify signal transduction pathways in cardiac myocytes that are specific for type I and type II isoforms of PKA. This will provide entry points for drug discovery efforts aimed at down-regulating specific isoforms of PKA that are associated with heart disease. First generation peptides that bind selectivity to type I and type II regulatory subunit isoforms of PKA have been designed. In phase I of this proposal we will optimize the peptides for cell permeability by attaching carrier molecules that facilitate membrane transport and evaluate their ability to interfere with PKA sub-cellular localization in an isoform-selective manner in adult rat cardiac myocytes. This research will establish proof of concept for a phase II project to evaluate the selective interference of these peptides in PKA-regulated ion channels that are known to be hyperphosphorylated and altered in heart failure and disease. Drug discovery efforts will be initiated for specific isoforms of PKA that alter ion channel function in heart disease. Optimized peptides in phase I of this project will be valuable tools for probing PKA-isoform-specific functions in many cell types and will be made available for use by the scientific research community.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R43
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    132414
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
    NHLBI:132414\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    PROVID PHARMACEUTICALS, INC
  • Organization Department
  • Organization DUNS
    031614444
  • Organization City
    NORTH BRUNSWICK
  • Organization State
    NJ
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    089023390
  • Organization District
    UNITED STATES